NCT06816212Enrolling by invitation
Correlation Between CEUS Identification of Nodular HPD on CE-MRI and Hepatic Malignant Lesions
Correlation Between CEUS Identification of Hepatic Nodular Perfusion Disorders on CE-MRI and Hepatic Malignant Lesions: a Prospective Multicenter Study
Source: ClinicalTrials.gov · Last updated 10 Feb 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Hepatic malignant tumors are a category of diseases with high incidence and mortality rates worldwide, including various types such as primary hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), and liver metastases. With the advancement of imaging technology, the number of hepatic perfusion disorders (HPD) detected in high-risk population screening and follow-up has gradually increased. However, the imaging manifestations of these HPD are highly heterogeneous, and the imaging features of some benign lesions (such as post-treatment inflammatory reactions, arterioportal shunts, hyperplastic nodules, focal fat deposition or fibrotic nodules) overlap with those of malignant lesions, posing a challenge to accurate diagnosis. Therefore, how to improve the ability to distinguish the benign and malignant nature of HPD based on multimodal imaging technology and optimize the follow-up management of high-risk populations has significant clinical value.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 280 (estimated)
- First submitted
- 4 Feb 2025
- Start date
- 10 Feb 2025
- Primary completion date
- 1 Feb 2027
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Diseases
- Childhood cancers
- NCT number
- NCT06816212
What you commit to
- Study type: Observational
- Planned participants: 280
- From 10 Feb 2025 to the primary completion date, 1 Feb 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients who unable to complete imaging examinations, such as severe cardiac insufficiency, severe renal insufficiency, hypersensitivity to contrast agents or adverse reactions to them, etc.
- Patients with the history of extensive liver resection or liver transplantation.
Other
- Patients whose abdomen with abundant intestinal gas.
Who the study is looking for
- Prospective cohort patients voluntarily sign the informed consent form.
- Patients with a history of malignant tumors, CE-MRI indicated the presence of HPD in the liver.
- The shape of HPD is nodular.
- The diameter of HPD is greater than 10mm.
- The main large vessels in the liver are clearly displayed in the MRI.
Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Ultrasound, Second Affiliated Hospital, School of Medicine, Zhejiang University Coordinator of this site? Confirm its status | Hangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.